Optimi Health

Impact: Optimi Health completed the first 2026 production and export of MDMA and psilocybin capsules to Australia, expanding its market access for psychedelic treatments for PTSD and TRD.

Impact: Optimi Health has secured ibogaine supply and is commencing development of finished drug products, positioning itself as a key supplier in the emerging psychedelic therapy market.

Impact: Optimi Health completed its first export of psilocybin to the United Kingdom for a Phase 2 clinical trial, expanding its international market reach and solidifying its position as a vertically integrated GMP supplier of psychedelic drug products. It also completed a GMP production run of 5mg psilocybin capsules, with some earmarked for clinical research in the United States and Europe.

Impact: Optimi Health Corp. has launched new microdose psilocybin products, expanding its product range and market reach for clinical research and therapeutic programs internationally. This development is expected to positively impact the company's revenue and market position.

Impact: Optimi Health completed its third commercial shipment of psilocybin to Australia, expanding its market presence and generating recurring revenue from the sale of its psychedelic drug products for medical use.